Does recombinant human growth hormone treatment improve AID pregnancy outcomes among patients with adavanced maternal age and poor prognosis: A prospective randomized controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068007

Enrollment

Unknown

Registered

2023-02-02

Start date

2021-01-01

Completion date

Unknown

Last updated

2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with adavanced maternal age and poor prognosis

Interventions

Control:standard AID

Growth Hormone Treatment:standard AID with growth hormone treatment for 6 weeks

Eligibility

Sex/Gender

Female

Age

35 Years to 42 Years

Inclusion criteria

Inclusion criteria: Patients who planned to recieve AID treatment will be screened in this study. the inclusion criteria are stated belowe 1. Age: 35-42 years old 2. Meet at least one of the following criteria: (1) AFC <=5 (2) AMH <=1.2ng/ml

Exclusion criteria

Exclusion criteria: 1. Patients with severe acute and chronic liver and kidney diseases, such as liver cirrhosis, acute and chronic renal failure, active hepatitis B virus, etc.; patients with abnormal liver and kidney functions, defined as AST/ALT/BUN elevation; 2. Uncontrolled endocrine and metabolic diseases and adrenal diseases, incluing: Hyperthyroidism, Cushing Syndrom, Hyperprolactinemia; 3. Rheumatic immune diseases; or are using immunosuppressive agents, including: SLE, SS, etc.; 4. Ovarian tumor with a diameter >= 4cm and the nature of the lesion has not been determined by surgery; 5. Combined with adenomyosis, ovarian endometriosis cyst with a diameter >= 4cm determined by B-ultrasound; Teratoma; All other malignancy; 6. Untreated hydrosalpinx, untreated endometrial lesions, uterine malformations, reproductive system tuberculosis; 7. Previous caesarean scar defect, hy drohystera, etc.; 8. Previous history of allergy to e-coli products, including insulin, growth factor, etc. ; 9. Tested positive for hepatitis B virus or hepatitis C virus; 10. Participating in other drug clinical investigators; 11. Others deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate;	—

Secondary

Measure	Time frame
Dominant Follicle Count;Diameter of the largest Dominant Follicle;Live Birth Rate;miscarriage rate;Estradiol level on ovulation day;Progesterone level on ovulation day;endometrium thickness on ovulation day;	—

Countries

China

Contacts

Public ContactJiang Ronghua

Reproductive medicine center of Guangdong Province Fertility Hospital

songgepp@126.com+86 13570493366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026